191 related articles for article (PubMed ID: 15522409)
1. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
Wu X; Patel D; Hasinoff BB
J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
[TBL] [Abstract][Full Text] [Related]
2. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
3. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186).
Hasinoff BB; Wu X; Yang Y
J Inorg Biochem; 2004 Apr; 98(4):616-24. PubMed ID: 15041241
[TBL] [Abstract][Full Text] [Related]
5. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
Malisza KL; Hasinoff BB
Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
[TBL] [Abstract][Full Text] [Related]
6. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug?
Hasinoff BB; Herman EH
Cardiovasc Toxicol; 2007; 7(2):140-4. PubMed ID: 17652819
[TBL] [Abstract][Full Text] [Related]
7. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Schroeder PE; Hasinoff BB
Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
[TBL] [Abstract][Full Text] [Related]
8. Chemistry of dexrazoxane and analogues.
Hasinoff BB
Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Schroeder PE; Hasinoff BB
Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
[TBL] [Abstract][Full Text] [Related]
10. The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces endopolyploidy in Chinese hamster ovary cells.
Hasinoff BB; Abram ME; Chee GL; Huebner E; Byard EH; Barnabé N; Ferrans VJ; Yu ZX; Yalowich JC
J Pharmacol Exp Ther; 2000 Nov; 295(2):474-83. PubMed ID: 11046078
[TBL] [Abstract][Full Text] [Related]
11. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187).
Buss JL; Hasinoff BB
Arch Biochem Biophys; 1995 Feb; 317(1):121-7. PubMed ID: 7872773
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
Schroeder PE; Wang GQ; Burczynski FJ; Hasinoff BB
Drug Metab Dispos; 2005 Jun; 33(6):719-25. PubMed ID: 15764716
[TBL] [Abstract][Full Text] [Related]
13. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines.
Hasinoff BB; Hellmann K; Herman EH; Ferrans VJ
Curr Med Chem; 1998 Feb; 5(1):1-28. PubMed ID: 9481032
[TBL] [Abstract][Full Text] [Related]
14. The one-ring open hydrolysis intermediates of the cardioprotective agent dexrazoxane (ICRF-187) do not inhibit the growth of Chinese hamster ovary cells or the catalytic activity of DNA topoisomerase II.
Hasinoff BB; Kuschak TI; Fattman CL; Yalowich JC
Anticancer Drugs; 1998 Jun; 9(5):465-71. PubMed ID: 9660545
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
16. The cardioprotective and DNA topoisomerase II inhibitory agent dexrazoxane (ICRF-187) antagonizes camptothecin-mediated growth inhibition of Chinese hamster ovary cells by inhibition of DNA synthesis.
Hasinoff BB; Chee GL; Thampatty P; Allan WP; Yalowich JC
Anticancer Drugs; 1999 Jan; 10(1):47-54. PubMed ID: 10194547
[TBL] [Abstract][Full Text] [Related]
17. Interaction of dexrazoxane with red blood cells and hemoglobin alters pharmacokinetics of doxorubicin.
Vaidyanathan S; Boroujerdi M
Cancer Chemother Pharmacol; 2000; 46(2):93-100. PubMed ID: 10972478
[TBL] [Abstract][Full Text] [Related]
18. [Dexrazoxane (ICRF-187)--a cardioprotectant and modulator of action of some anticancer drugs].
Kik K; Szmigiero L
Postepy Hig Med Dosw (Online); 2006; 60():584-90. PubMed ID: 17115008
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
20. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
Hasinoff BB
Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]